A revolutionary treatment with ethical and regulatory considerations!
The Future of CRISPR-Based Therapies for Sickle Cell Anemia
Overcoming Challenges to Achieve a Cure
In the recent decade, particularly after the birth of Lulu and Nana in a Chinese laboratory, the medical community has been intrigued by the potential of CRISPR-based therapies. This scientific breakthrough has recently opened a new door in the fight against sickle cell disease (SCD), affecting hundreds of thousands worldwide.
Sickle cell disease is a debilitating blood disorder that results in an anomaly in the oxygen-carrying protein hemoglobin found in red blood cells. This anomaly causes a rigid, sickle-like shape under certain circumstances.
The contemporary innovative technique, also known as Casgevy, utilizes the precision of CRISPR/Cas9 genome editing to boost the production of hemoglobin type primarily present in fetal blood in patients' hematopoietic (blood-producing) stem cells. The result?
